Ipsen shares rise driven by FY results beat

Ipsen SA

12/02/2026 11:20

** Shares of French biotechnology company Ipsen IPN.PA jump 8.5% after its FY results beat consensus, driven by strong performance in oncology and robust sales from newly launched liver disease drug Iqirvo

** Ipsen's FY EBIT of 1.29 billion euros ($1.53 billion) beats consensus by 4%

** Jefferies also says the "strong initial 2026 outlook," with potential sales and profit upgrades, supported by the continued hormone drug Somatuline windfall amidst generic shortages

** Ipsen expects 2026 total sales growth of over 13% at CER and an operating margin of more than 35%

** Shares are on track for their best day since July 2022

($1 = 0.8426 euros)

(Reporting by Jerome Terroy)

((jerome.terroy@thomsonreuters.com))